Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.

OBJECTIVE The aim of this study was to evaluate the differentially secreted protein profile in the urine from patients with clear cell renal cell carcinoma (ccRCC) using mass spectrometry-based methods. Urine composition can reflect kidney physiology and can be used to detect markers for renal diseases. Moreover, characterization of the secretome is likely to assist in the investigation of new drugs for biological targets and diagnose the ccRCC at an early stage. METHODS AND MATERIALS Urine samples from patients were divided according to Fuhrman degree (FI-IV), which was associated with the cellular differentiation as good prognosis (GP) and poor prognosis (PP). Healthy individuals were used as the control group (CG). We used both qualitative and quantitative mass spectrometry-based analyses that involved the following approaches: 1-dimensional gel electrophoresis combined with liquid chromatography mass spectrometry in tandem (1DE LC-MS/MS), in-solution digestion combined with label-free 1-dimensional LC-MS(E) (1D LC-MS(E)), and bidimensional gel electrophoresis combined with matrix-assisted laser desorption/ionization time of flight in tandem (2DE MALDI-TOF/TOF) or combined with LC-MS/MS. RESULTS All the strategies allowed the identification of 354 proteins from the CG, GP, and PP groups. Qualitative experiments using 1DE LC-MS/MS analysis detected different protein profiles, and 224 proteins were identified in all groups. The label-free MS(E) quantitative analysis identified 113 proteins and generated novel information on secreted protein profiles, including 49 up-secreted proteins in the urine from patients with ccRCC and 40 down-secreted proteins related to the CG. Proteins such as kininogen-1, uromodulin, apolipoprotein D, polyubiquitin, and CD59 glycoprotein were down secreted according to the groups CG>GP>PP. In contrast, apolipoprotein A, fibrinogen, and haptoglobin were up secreted in patient groups. The same expression profile observed for kininogen-1, apolipoprotein D, fibrinogen, and haptoglobin was corroborated by 2DE LC-MS/MS or 2DE MALDI-TOF/TOF analyses. These 2 strategies also showed 13 differentially secreted proteins among the 3 groups. CONCLUSIONS The proteins kininogen-1, apolipoprotein D, fibrinogen, and haptoglobin presented similar quantitative protein profiles according to MS(E) and 2DE approaches. The latter proteins were up secreted and the former ones were down-regulated. The strategies used proved to be valuable in identifying proteins that were differentially secreted in urine from patients with RCC.

[1]  W. Rathmell,et al.  Renal cell carcinoma , 2007, Current opinion in oncology.

[2]  S. Herrell,et al.  Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. , 2015, Urologic oncology.

[3]  O. Hashim,et al.  Identification of O-glycosylated Proteins That Are Aberrantly Excreted in the Urine of Patients with Early Stage Ovarian Cancer , 2013, International journal of molecular sciences.

[4]  O. Hashim,et al.  Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin , 2010, Proteome Science.

[5]  G. Yousef,et al.  Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. , 2009, Journal of proteome research.

[6]  E. Rech,et al.  Detection and expression analysis of recombinant proteins in plant-derived complex mixtures using nanoUPLC-MS(E). , 2011, Journal of separation science.

[7]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[8]  K. Pummer,et al.  High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients , 2013, British Journal of Cancer.

[9]  Martin Norling,et al.  Comprehensive human urine standards for comparability and standardization in clinical proteome analysis , 2010, Proteomics. Clinical applications.

[10]  J. Goldblum,et al.  Apolipoprotein D is down-regulated during malignant transformation of neurofibromas. , 2005, Human pathology.

[11]  Stefano Ferrero,et al.  Human urine biomarkers of renal cell carcinoma evaluated by ClinProt , 2008, Proteomics. Clinical applications.

[12]  G. Mauri,et al.  Urinary Signatures of Renal Cell Carcinoma Investigated by Peptidomic Approaches , 2014, PloS one.

[13]  G. Candiano,et al.  From hundreds to thousands: Widening the normal human Urinome , 2014, Data in brief.

[14]  V. Sandim,et al.  Renal Cell Carcinoma and Proteomics , 2010, Urologia Internationalis.

[15]  Hersh Chandarana,et al.  Contemporary imaging of the renal mass. , 2012, The Urologic clinics of North America.

[16]  G. Domont,et al.  Differencial proteome of clear-cell renal cell carcinoma (ccRCC) tissues. , 2013, International braz j urol : official journal of the Brazilian Society of Urology.

[17]  Yi-ding Chen,et al.  Urinary proteomics as a novel tool for biomarker discovery in kidney diseases , 2010, Journal of Zhejiang University SCIENCE B.

[18]  J. Patard,et al.  Renal cell carcinoma guideline. , 2007, European urology.

[19]  Rembert Pieper,et al.  Characterization of the human urinary proteome: A method for high‐resolution display of urinary proteins on two‐dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots , 2004, Proteomics.

[20]  Ming Li,et al.  PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. , 2003, Rapid communications in mass spectrometry : RCM.

[21]  A. Borowsky,et al.  Grade-dependent Proteomics Characterization of Kidney Cancer*S , 2009, Molecular & Cellular Proteomics.

[22]  M. Mann,et al.  Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. , 2011, Journal of proteome research.

[23]  Urine screening by Seldi-Tof, followed by biomarker identification, in a Brazilian cohort of patients with renal cell carcinoma (RCC). , 2013, International braz j urol : official journal of the Brazilian Society of Urology.

[24]  Chun-Liang Tung,et al.  Proteomics-based identification of plasma biomarkers in oral squamous cell carcinoma. , 2013, Journal of pharmaceutical and biomedical analysis.

[25]  Danny C. Kim,et al.  Contemporary Imaging of the Renal Mass , 2011, Current urology reports.

[26]  A. Pantuck,et al.  Molecular biology of renal cortical tumors. , 2008, The Urologic clinics of North America.

[27]  W. Davidson,et al.  Apolipoprotein A-I mimetics and high-density lipoprotein function , 2012, Current opinion in endocrinology, diabetes, and obesity.

[28]  M. Silva-Neto,et al.  Four conventional soybean [Glycine max (L.) Merrill] seeds exhibit different protein profiles as revealed by proteomic analysis. , 2014, Journal of agricultural and food chemistry.

[29]  Giuseppe Di Lorenzo,et al.  Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal Cell Cacinoma Guideline. Eur Urol 2007;51:1502–10 , 2007 .

[30]  V. Thongboonkerd,et al.  Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: quantity, quality, and variability. , 2006, Journal of proteome research.

[31]  P. Rudd,et al.  Acute phase glycoproteins: bystanders or participants in carcinogenesis? , 2012, Annals of the New York Academy of Sciences.